Resources from the same session
799MO - The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
Presenter: Ling Pan
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
800MO - First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study
Presenter: Junyuan Qi
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
801MO - Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)
Presenter: Liya Ma
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 799MO, 800MO and 801MO
Presenter: Sara Garrido Paniagua
Session: Mini oral session 1: Haematological malignancies
Resources:
Slides
Webcast
802MO - Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
Presenter: Junmin Song
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Webcast
803MO - CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis
Presenter: Myriam BEN KHELIL
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
804MO - Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity
Presenter: Laura MARCOS-KOVANDZIC
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
805MO - Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry
Presenter: Loic Ysebaert
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Presenter: Armin Ghobadi
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
807MO - High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients
Presenter: Lei Yu
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast